RenovoRx, Inc. (RNXT) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
RNXT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, RenovoRx, Inc. (RNXT) trades at a price-to-earnings ratio of -2.3x, with a stock price of $0.86 and trailing twelve-month earnings per share of $-0.30.
Compared to the Healthcare sector median P/E of 22.2x, RNXT trades at a 111% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, RNXT trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RNXT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RNXT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $234M | 4.7Lowest | 4.67 | +49% | |
| $8B | 25.0 | 1.09 | -25% | |
| $2B | 6.9 | 0.67Best | +817% | |
| $7B | 15.5 | - | +1747%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See RNXT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RNXT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RNXT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRNXT — Frequently Asked Questions
Quick answers to the most common questions about buying RNXT stock.
Is RNXT stock overvalued or undervalued?
RNXT current P/E: -2.3x. 5-year average P/E: N/A. Percentile: N/A.
How does RNXT's valuation compare to peers?
RenovoRx, Inc. P/E of -2.3x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is RNXT's PEG ratio?
RNXT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.